TY - JOUR
T1 - Colorectal liver metastases
T2 - Resect, ablate, or embolize
AU - Leigh, Natasha
AU - Sanford, Dominic E.
N1 - Funding Information:
None.
Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/9
Y1 - 2023/9
N2 - The management of colorectal liver metastases (CRLM) is complex and should be individualized to each patient. Resectable CRLM benefit from surgical resection, preferably minimally invasive and parenchymal sparing, when feasible. Ablation is a viable alternative. Chemotherapy in this setting is potentially indicated in select patients, however, it has a clear role in unresectable CRLM. Newer locoregional therapies may benefit some unresectable CRLM with resistance to chemotherapy. Liver transplantation, a new therapy on the horizon for unresectable disease, has encouraging preliminary long-term survival outcomes for carefully selected patients.
AB - The management of colorectal liver metastases (CRLM) is complex and should be individualized to each patient. Resectable CRLM benefit from surgical resection, preferably minimally invasive and parenchymal sparing, when feasible. Ablation is a viable alternative. Chemotherapy in this setting is potentially indicated in select patients, however, it has a clear role in unresectable CRLM. Newer locoregional therapies may benefit some unresectable CRLM with resistance to chemotherapy. Liver transplantation, a new therapy on the horizon for unresectable disease, has encouraging preliminary long-term survival outcomes for carefully selected patients.
KW - Ablation
KW - Chemotherapy
KW - Colorectal liver metastases
KW - Embolization
KW - Hepatectomy
UR - http://www.scopus.com/inward/record.url?scp=85162171348&partnerID=8YFLogxK
U2 - 10.1016/j.scrs.2023.100968
DO - 10.1016/j.scrs.2023.100968
M3 - Review article
AN - SCOPUS:85162171348
SN - 1043-1489
VL - 34
JO - Seminars in Colon and Rectal Surgery
JF - Seminars in Colon and Rectal Surgery
IS - 3
M1 - 100968
ER -